Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cystic Fibrosis: Management01:24

Cystic Fibrosis: Management

656
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
656
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

1.2K
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
1.2K
Therapeutic Drug Monitoring: Affecting Factors01:29

Therapeutic Drug Monitoring: Affecting Factors

400
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
400
FDA Approved Drugs: Changes to Approved Drugs01:26

FDA Approved Drugs: Changes to Approved Drugs

336
Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
336
Modified-Release Drug Delivery Systems: Rate-Programmed II01:19

Modified-Release Drug Delivery Systems: Rate-Programmed II

108
Rate-programmed drug delivery systems release drugs in a controlled manner to maintain therapeutic levels. Three main designs include reservoir, matrix, and hybrid systems.Reservoir systems consist of a drug core enclosed within a membrane that controls drug release. In non-swelling reservoir systems, polymers like ethyl cellulose or polymethacrylates are used. These do not hydrate in aqueous media and control release through membrane thickness, porosity, or insolubility. This type includes...
108
Cystic Fibrosis: Pathogenesis01:23

Cystic Fibrosis: Pathogenesis

1.1K
Cystic fibrosis (CF), an autosomal recessive disorder, significantly affects the function of exocrine glands. This genetically inherited disease is characterized by the production of thick and sticky mucus, which can severely affect various organs and systems in the body.
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
1.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Magneto-Electrochemical Nanobioelectronic Device for Simultaneous Extraction and On-chip Detection of Cancer Biomarker in Cell Lysate.

Small (Weinheim an der Bergstrasse, Germany)·2026
Same author

Visualizing immunoreceptor forces and their effects in vivo.

bioRxiv : the preprint server for biology·2026
Same author

Smoking inequalities among culturally diverse populations in Australia: A secondary dataset analysis of the HILDA survey 2002-2019.

Tobacco induced diseases·2026
Same author

Activating antiviral defenses warms up cold tumours.

Nature nanotechnology·2026
Same author

The Impact of Front-of-Pack Labeling on Social Inequality in Sugar Consumption and Purchase: A Systematic Review.

Obesity reviews : an official journal of the International Association for the Study of Obesity·2026
Same author

DNA cross-over motifs-based, programmable supramolecular hydrogels for the mechanoregulatory effects of cellular behaviour and cytoskeleton reorganization.

npj biomedical innovations·2026

Related Experiment Video

Updated: Apr 18, 2026

Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients
06:14

Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients

Published on: October 15, 2017

8.9K

Ivacaftor: a novel mutation modulating drug.

Harit Kapoor1, Astha Koolwal1, Ankur Singh2

  • 1Student, Theni Government Medical College , Tamil Nadu, India .

Journal of Clinical and Diagnostic Research : JCDR
|January 14, 2015
PubMed
Summary

Cystic fibrosis (CF) is a genetic disorder affecting multiple systems, primarily the lungs. Ivacaftor, a personalized medicine, targets specific CF transmembrane conductance regulator gene mutations, improving lung function and patient outcomes.

Keywords:
Cystic fibrosisIvacaftor

More Related Videos

Forskolin-induced Swelling in Intestinal Organoids: An In Vitro Assay for Assessing Drug Response in Cystic Fibrosis Patients
07:04

Forskolin-induced Swelling in Intestinal Organoids: An In Vitro Assay for Assessing Drug Response in Cystic Fibrosis Patients

Published on: February 11, 2017

20.3K
Functional Reconstitution and Channel Activity Measurements of Purified Wildtype and Mutant CFTR Protein
09:59

Functional Reconstitution and Channel Activity Measurements of Purified Wildtype and Mutant CFTR Protein

Published on: March 9, 2015

12.8K

Related Experiment Videos

Last Updated: Apr 18, 2026

Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients
06:14

Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients

Published on: October 15, 2017

8.9K
Forskolin-induced Swelling in Intestinal Organoids: An In Vitro Assay for Assessing Drug Response in Cystic Fibrosis Patients
07:04

Forskolin-induced Swelling in Intestinal Organoids: An In Vitro Assay for Assessing Drug Response in Cystic Fibrosis Patients

Published on: February 11, 2017

20.3K
Functional Reconstitution and Channel Activity Measurements of Purified Wildtype and Mutant CFTR Protein
09:59

Functional Reconstitution and Channel Activity Measurements of Purified Wildtype and Mutant CFTR Protein

Published on: March 9, 2015

12.8K

Area of Science:

  • Medical Genetics
  • Pulmonology
  • Pharmacology

Background:

  • Cystic fibrosis (CF) is a multisystemic genetic disorder affecting individuals from birth to adulthood.
  • It predominantly impacts the respiratory system and is caused by mutations in the CF transmembrane conductance regulator (CFTR) gene.
  • The ΔF508 mutation is the most prevalent globally, while supportive therapies form the cornerstone of current management.

Purpose of the Study:

  • To review the efficacy and safety of Ivacaftor, a mutation-specific drug for cystic fibrosis.
  • To highlight the significance of Ivacaftor as an example of personalized medicine in treating CF.

Main Methods:

  • Review of clinical data and FDA approval information for Ivacaftor.
  • Summary of Ivacaftor's mechanism of action and therapeutic targets.
  • Analysis of patient outcomes and side effect profiles.

Main Results:

  • Ivacaftor, approved in 2012 for the G551D mutation, is administered at 150 mg twice daily with fatty meals for patients aged six and older.
  • The drug significantly improves lung function and promotes weight gain in treated individuals.
  • Reported side effects, including upper respiratory infections and gastrointestinal disturbances, are generally mild and transient.

Conclusions:

  • Ivacaftor represents a breakthrough in personalized medicine, offering targeted treatment for CF patients with specific genetic mutations.
  • This targeted approach demonstrates the potential for tailored therapies to significantly improve disease management and patient quality of life.